Analyst Reco. Haemonetics Corporation

Equities

HAE

US4050241003

Market Closed - Nyse Other stock markets 04:00:02 2024-05-31 pm EDT			5-day change	1st Jan Change
84.08 ^USD	-0.67%		-4.82%	-1.67%

May. 29	Haemonetics Insider Sold Shares Worth $1,144,208, According to a Recent SEC Filing	MT
May. 29	Haemonetics Insider Sold Shares Worth $775,253, According to a Recent SEC Filing	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Haemonetics Insider Sold Shares Worth $1,144,208, According to a Recent SEC Filing	May. 29	MT
Haemonetics Insider Sold Shares Worth $775,253, According to a Recent SEC Filing	May. 29	MT
Haemonetics Insider Sold Shares Worth $254,443, According to a Recent SEC Filing	May. 21	MT
Barrington Research Raises Price Target on Haemonetics to $107 From $105, Keeps Outperform Rating	May. 10	MT
Barrington Cuts Price Target on Haemonetics to $105 From $114 on 'Macro Concerns', Keeps Outperform Rating	Nov. 03	MT
Citigroup Raises Haemonetics' Price Target to $94 From $90, Keeps Neutral Rating	23-10-02	MT
Barrington Raises Price Target on Haemonetics to $114 From $111, Keeps Outperform Rating	23-08-09	MT
Morgan Stanley Adjusts Price Target on Haemonetics to $96 From $88, Maintains Equal-Weight Rating	23-05-12	MT
Barrington Ups Price Target on Haemonetics to $111 From $103, Keeps Outperform Rating	23-05-12	MT
JMP Securities Adjusts Price Target on Haemonetics to $115 From $105, Maintains Market Outperform Rating	23-05-12	MT
Morgan Stanley Raises Haemonetics' Price Target to $88 From $84, Maintains Equalweight Rating	23-02-08	MT
Mizuho Securities Adjusts Price Target on Haemonetics to $115 From $110, Maintains Buy Rating	23-02-08	MT
Citigroup Raises Haemonetics' Price Target to $95 From $92, Maintains Neutral Rating	23-02-08	MT
Barrington Research Raises Haemonetics' Price Target to $103 From $94, Maintains Outperform Rating	23-02-08	MT
Mizuho Adjusts Haemonetics' Price Target to $110 From $100, Keeps Buy Rating	23-01-24	MT
Morgan Stanley Cuts Price Target on Haemonetics to $84 From $90, Reiterates Equalweight Rating	23-01-06	MT
Citigroup Boosts Price Target on Haemonetics to $92 From $88, Affirms Neutral Rating	22-12-12	MT
Citigroup Adjusts Price Target on Haemonetics to $88 From $80, Maintains Neutral Rating	22-11-08	MT
Barrington Hikes Price Target for Haemonetics to $94 From $88, Keeps Outperform Rating	22-11-08	MT
Morgan Stanley Adjusts Price Target on Haemonetics to $90 From $85, Maintains Equalweight Rating	22-11-08	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Haemonetics Corporation

Equities

HAE

US4050241003

Analyst Reco.

Filters